Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

Musa Yilmaz, Hagop Kantarjian, Elias Jabbour, Susan O'Brien, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Farhad Ravandi, Jan Burger, Sherry Pierce, Alfonso Quintas-Cardama, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Introduction Outcomes of CML-CP patients treated in clinical trials are frequently perceived to be not representative of those treated outside of clinical trials. Patients and Methods We investigated the outcomes of patients receiving imatinib outside of a clinical trial (off protocol) or in a clinical trial (on protocol) for CML-CP. Results We identified 65 patients treated with imatinib off protocol and 71 patients treated on protocol with standard-dose imatinib. The overall complete cytogenetic response (CCyR) rate was 83% for patients treated on and off protocol. CCyR rates 12 months after initiation of imatinib were not statistically different (61% vs. 66%, respectively; P =.15). Patients treated off protocol had similar rates of overall major molecular response (72% vs. 73%) compared with the patients treated on protocol. The 5-year event-free survival rates were 84% and 86% for off and on protocol patients, respectively. There was also no significant difference in 5-year transformation free survival (94% vs. 96%) and overall survival (96% vs. 90%). Conclusion These results suggest that patients with CML treated outside of a clinical trial might have the same excellent outcome as those treated in a clinical trial provided they are followed with the same rigor.

Original languageEnglish (US)
Pages (from-to)693-699
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number6
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Trials
Clinical Protocols
Cytogenetics
Imatinib Mesylate
Survival
Disease-Free Survival
Survival Rate

Keywords

  • CML
  • Imatinib
  • Outside of a clinical trial
  • Prognosis
  • TKI

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. / Yilmaz, Musa; Kantarjian, Hagop; Jabbour, Elias; O'Brien, Susan; Borthakur, Gautam; Verstovsek, Srdan; Garcia-Manero, Guillermo; Ravandi, Farhad; Burger, Jan; Pierce, Sherry; Quintas-Cardama, Alfonso; Cortes, Jorge.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 6, 01.12.2013, p. 693-699.

Research output: Contribution to journalArticle

Yilmaz, M, Kantarjian, H, Jabbour, E, O'Brien, S, Borthakur, G, Verstovsek, S, Garcia-Manero, G, Ravandi, F, Burger, J, Pierce, S, Quintas-Cardama, A & Cortes, J 2013, 'Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials', Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 6, pp. 693-699. https://doi.org/10.1016/j.clml.2013.05.011
Yilmaz, Musa ; Kantarjian, Hagop ; Jabbour, Elias ; O'Brien, Susan ; Borthakur, Gautam ; Verstovsek, Srdan ; Garcia-Manero, Guillermo ; Ravandi, Farhad ; Burger, Jan ; Pierce, Sherry ; Quintas-Cardama, Alfonso ; Cortes, Jorge. / Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 6. pp. 693-699.
@article{fa07ebb1ace2465d9d4f364261b7d29c,
title = "Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials",
abstract = "Introduction Outcomes of CML-CP patients treated in clinical trials are frequently perceived to be not representative of those treated outside of clinical trials. Patients and Methods We investigated the outcomes of patients receiving imatinib outside of a clinical trial (off protocol) or in a clinical trial (on protocol) for CML-CP. Results We identified 65 patients treated with imatinib off protocol and 71 patients treated on protocol with standard-dose imatinib. The overall complete cytogenetic response (CCyR) rate was 83{\%} for patients treated on and off protocol. CCyR rates 12 months after initiation of imatinib were not statistically different (61{\%} vs. 66{\%}, respectively; P =.15). Patients treated off protocol had similar rates of overall major molecular response (72{\%} vs. 73{\%}) compared with the patients treated on protocol. The 5-year event-free survival rates were 84{\%} and 86{\%} for off and on protocol patients, respectively. There was also no significant difference in 5-year transformation free survival (94{\%} vs. 96{\%}) and overall survival (96{\%} vs. 90{\%}). Conclusion These results suggest that patients with CML treated outside of a clinical trial might have the same excellent outcome as those treated in a clinical trial provided they are followed with the same rigor.",
keywords = "CML, Imatinib, Outside of a clinical trial, Prognosis, TKI",
author = "Musa Yilmaz and Hagop Kantarjian and Elias Jabbour and Susan O'Brien and Gautam Borthakur and Srdan Verstovsek and Guillermo Garcia-Manero and Farhad Ravandi and Jan Burger and Sherry Pierce and Alfonso Quintas-Cardama and Jorge Cortes",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.clml.2013.05.011",
language = "English (US)",
volume = "13",
pages = "693--699",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

AU - Yilmaz, Musa

AU - Kantarjian, Hagop

AU - Jabbour, Elias

AU - O'Brien, Susan

AU - Borthakur, Gautam

AU - Verstovsek, Srdan

AU - Garcia-Manero, Guillermo

AU - Ravandi, Farhad

AU - Burger, Jan

AU - Pierce, Sherry

AU - Quintas-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Introduction Outcomes of CML-CP patients treated in clinical trials are frequently perceived to be not representative of those treated outside of clinical trials. Patients and Methods We investigated the outcomes of patients receiving imatinib outside of a clinical trial (off protocol) or in a clinical trial (on protocol) for CML-CP. Results We identified 65 patients treated with imatinib off protocol and 71 patients treated on protocol with standard-dose imatinib. The overall complete cytogenetic response (CCyR) rate was 83% for patients treated on and off protocol. CCyR rates 12 months after initiation of imatinib were not statistically different (61% vs. 66%, respectively; P =.15). Patients treated off protocol had similar rates of overall major molecular response (72% vs. 73%) compared with the patients treated on protocol. The 5-year event-free survival rates were 84% and 86% for off and on protocol patients, respectively. There was also no significant difference in 5-year transformation free survival (94% vs. 96%) and overall survival (96% vs. 90%). Conclusion These results suggest that patients with CML treated outside of a clinical trial might have the same excellent outcome as those treated in a clinical trial provided they are followed with the same rigor.

AB - Introduction Outcomes of CML-CP patients treated in clinical trials are frequently perceived to be not representative of those treated outside of clinical trials. Patients and Methods We investigated the outcomes of patients receiving imatinib outside of a clinical trial (off protocol) or in a clinical trial (on protocol) for CML-CP. Results We identified 65 patients treated with imatinib off protocol and 71 patients treated on protocol with standard-dose imatinib. The overall complete cytogenetic response (CCyR) rate was 83% for patients treated on and off protocol. CCyR rates 12 months after initiation of imatinib were not statistically different (61% vs. 66%, respectively; P =.15). Patients treated off protocol had similar rates of overall major molecular response (72% vs. 73%) compared with the patients treated on protocol. The 5-year event-free survival rates were 84% and 86% for off and on protocol patients, respectively. There was also no significant difference in 5-year transformation free survival (94% vs. 96%) and overall survival (96% vs. 90%). Conclusion These results suggest that patients with CML treated outside of a clinical trial might have the same excellent outcome as those treated in a clinical trial provided they are followed with the same rigor.

KW - CML

KW - Imatinib

KW - Outside of a clinical trial

KW - Prognosis

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=84887999856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887999856&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.05.011

DO - 10.1016/j.clml.2013.05.011

M3 - Article

C2 - 24060289

AN - SCOPUS:84887999856

VL - 13

SP - 693

EP - 699

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 6

ER -